ABSTRACT NUMBER: ESOC2026LB157 LB157 - INCIDENT ISCHAEMIC STROKE IN THE RANDOMISED, PLACEBO-CONTROLLED, EVENT-DRIVEN OCEANIC-STROKE TRIAL OF ASUNDEXIAN FOR SECONDARY STROKE PREVENTION: SEVERITY, TREATMENT AND OUTCOMES
Mukul Sharma, Qiang Dong, Teruyuki Hirano, Scott Kasner, Jeffrey Saver, Jaime Masjuan, Andrew Demchuk, Eva Muehlhofer, Karleen Schulze, Ashkan Shoamanesh · 2026
Read ABSTRACT NUMBER: ESOC2026LB157 LB157 - INCIDENT ISCHAEMIC STROKE IN THE RANDOMISED, PLACEBO-CONTROLLED, EVENT-DRIVEN OCEANIC-STROKE TRIAL OF ASUNDEXIAN FOR SECONDARY STROKE PREVENTION: SEVERITY, TREATMENT AND OUTCOMES by Mukul Sharma, Qiang Dong, Teruyuki Hirano, Scott Kasner, Jeffrey Saver, Jaime Masjuan, Andrew Demchuk, Eva Muehlhofer, Karleen Schulze, Ashkan Shoamanesh (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13145132.txt.
Description
Mukul Sharma and co-authors look in depth at the strokes that still took place in a large drug trial. Their conference abstract from 2026 covers a trial of asundexian, a new blood thinning drug, added to standard care after stroke or mini stroke. The drug cut new strokes overall in the main trial.
More than twelve thousand people took part. New strokes took place in 384 people on the drug and 518 on dummy pills. Severe strokes were less common in the drug group, and disabling strokes fell as well. Fewer people in the drug group needed clot removal for their new stroke. Outcomes after acute care for those strokes are also set out.
Catalog record
| CREATOR | Mukul Sharma, Qiang Dong, Teruyuki Hirano, Scott Kasner, Jeffrey Saver, Jaime Masjuan, Andrew Demchuk, Eva Muehlhofer, Karleen Schulze, Ashkan Shoamanesh |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |